After intracerebral convection-enhanced delivery (CED) of IL13-PE was determined to be feasible and safe in Phase 1/2 clinical trials (49, 50), a randomized Phase 3 trial (PRECISE) with intraparenchymal IL-13PE administration was initiated in GBM patients. The gene discussed is IL13; the disease is glioblastoma.